Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping

By sjmartinez • May 3, 2025

Cavanaugh D, Holt SK, Dwyer E, Petersen E, Gore JL, Schade GR, Grivas P, Hsieh AC, Lee JK, Montgomery B, Schweizer MT, Yezefski T, Yu EY, Chen JJ, Liao JJ, Weg E, Zeng J, Jannat S, Berry DL, Master VA, Garcia JM, Reed MJ, Bentov I, Wright JL, Psutka SP. Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping. Urol Oncol. 2025 May 1:S1078-1439(25)00123-1. doi: 10.1016/j.urolonc.2025.03.025. Epub ahead of print. PMID: 40316478.

Tags: Hematology/Oncology, Publications

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]